WUND Healing Biopharmaceuticals

What WUND Healing Biopharmaceuticals does

WUND Healing Biopharmaceuticals is a private, preclinical biopharmaceutical company founded in May 2016 and headquartered in Las Vegas, Nevada. The company holds exclusive licensing rights for the United States and Canada to a portfolio of FGF-1 (Fibroblast Growth Factor 1) drug candidates originally developed by Zhittya Genesis Medicine. Its scientific platform is therapeutic angiogenesis — leveraging FGF-1 to stimulate the formation of new blood vessels — applied across a broad pipeline that includes Parkinson's disease, multiple sclerosis, heart disease and stroke, diabetic foot ulcers, traumatic brain injury, Type 2 diabetes, lung disease, and COVID-19-related lung damage.

The company has no FDA-approved products and operates with a headcount of 1-10 employees. The most advanced disclosed clinical signal comes from the licensor's Parkinson's program, in which over 200 patients have reportedly been treated in studies conducted in the British Virgin Islands, with reported motor function improvements of approximately 54%. No funding rounds, revenue, or commercial partnerships have been disclosed in the available information.

The business model is structured around advancing the in-licensed FGF-1 candidates through clinical development in the US and Canada, with future monetization dependent on either direct commercialization of approved products in those territories or out-licensing/partnering arrangements for late-stage development and market access. Leadership comprises CEO John Laub and Directors James Lamb and Gregory Fey.

Name

WUND Healing Biopharmaceuticals

Legal name

Wund Healing Biopharmaceuticals, Inc.

Website

https://wundbio.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

WUND Healing Biopharmaceuticals is a preclinical Las Vegas-based biopharmaceutical company that holds exclusive US and Canada licensing rights to FGF-1 therapeutic angiogenesis drug candidates originally developed by Zhittya Genesis Medicine, targeting ischemic and degenerative diseases including Parkinson's, MS, and diabetic foot ulcers.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Therapeutic angiogenesis drugs
• Fibroblast growth factor therapy
• Biopharmaceutical drug development
• Neurological disease therapeutics
• Wound healing biologics

Headquarters

HQ city

Las Vegas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Sales: Once regulatory approval is obtained, the company plans to commercialize FGF-1 based therapeutics for Parkinson's disease, heart disease, stroke, diabetic foot ulcers, multiple sclerosis, type 2 diabetes, and lung diseases. Revenue will be generated through prescription drug sales in the US and Canada under exclusive licensing rights from Zhittya Genesis Medicine.

Go-to-market motion1 record

Marketing channels5 records

Core offering

WUND Healing Biopharmaceuticals is a pre-commercial biopharmaceutical company developing a portfolio of FGF-1 (fibroblast growth factor 1) based therapeutics using therapeutic angiogenesis. The company develops treatments for Parkinson's disease, heart disease, stroke, diabetic foot ulcers, multiple sclerosis, type 2 diabetes, traumatic brain injury, and lung diseases, delivered via nasal inhaler, inhalation, injection, or topical application under exclusive US and Canada licensing rights from Zhittya Genesis Medicine.

Product overview

WUND Healing Biopharmaceuticals is a biopharmaceutical company developing a portfolio of FGF-1 (fibroblast growth factor 1) based therapies for multiple conditions. The company's core technology platform centers on therapeutic angiogenesis using human FGF-1, a natural protein that stimulates blood vessel growth. The product line includes treatments for Parkinson's Disease, Multiple Sclerosis, Heart Disease and Stroke, Diabetic Foot Ulcers, Traumatic Brain Injury, Type 2 Diabetes, COVID-19 Lung Damage, and general Lung Diseases. All products share the same FGF-1 molecule delivered via different routes (nasal inhaler for neurological conditions, topical for wounds, inhaled for lung conditions, injection for heart disease) to treat conditions linked to reduced blood perfusion.

Differentiator

Problem solved

Functional benefit

Products and services

• FGF-1 Therapy for Type 2 Diabetes

Quantifiable outcome

• 54% average improvement in motor skills within six months for Parkinson's disease patients receiving intranasal FGF-1 therapy
• +2 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Zhittya Genesis MedicinecoreOEM/ Whitelabel/ Licensing Partner · 1 May 2016WUND Healing Biopharmaceuticals owns exclusive licensing rights for the United States and Canada to market and sell drugs developed by Zhittya Genesis Medicine. Zhittya Genesis Medicine is developing drugs based on fibroblast growth factor 1 (FGF-1) to stimulate the body's growth of blood vessels and nerves. The partnership enables WUND to commercialize FGF-1 based treatments for Parkinson's disease, heart disease, stroke, diabetic foot ulcers, MS, and other diseases in the licensed territories. WUND is also referred to as forwarding clinical trial information requests to Zhittya Genesis Medicine as their Clinical Research Partner.

Scale indicators5 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Helixmith: Helixmith develops angiogenic gene therapies (e.g., VM202/Donaperminogene Sarcoplasmogene) targeting peripheral neuropathy, ischemic heart disease, and diabetic foot ulcers — directly comparable therapeutic class and indications to WUND's FGF-1 portfolio.
• AnGes: AnGes is a Japanese biopharmaceutical company developing gene and protein therapeutics for angiogenesis-related indications including peripheral artery disease and diabetic foot ulcers — the closest direct therapeutic-area comparable to WUND's FGF-1 platform.
• Capricor Therapeutics: Capricor develops cell-derived regenerative therapies for cardiac and Duchenne muscular dystrophy indications — comparable regenerative platform approach targeting cardiac disease states similar to WUND.
• Healios: Healios develops cell and regenerative therapies for stroke, ARDS, and other ischemic conditions — directly comparable regenerative-medicine approach to ischemic injury that overlaps with WUND's stroke and lung indications.
• VBL Therapeutics: VBL Therapeutics develops vascular biology-driven therapeutics (e.g., ofranergene obadenovec gene therapy) targeting solid tumors and inflammatory indications — overlapping angiogenic-mechanism approach with WUND.
• Capstone Therapeutics (Angionetics): Capstone/Angionetics is developing angiogenic biologic therapies for cardiovascular and ischemic indications, sharing WUND's therapeutic angiogenesis thesis and cardiac/stroke focus.

Broad incumbents

• FibroGen: FibroGen is the largest developer of FGF-based therapeutics (notably roxadustat for anemia) and shares the FGF-1 mechanistic foundation with WUND, though FibroGen is far broader and more commercially advanced.
• MiMedx: MiMedx develops placental tissue-based regenerative products for wound care and surgical recovery — relevant comparable for WUND's diabetic foot ulcer and wound healing therapeutic area.
• Organogenesis: Organogenesis is a commercial-stage regenerative medicine company with leading wound-care and skin-substitute products (Apligraf, Dermagraft) — directly relevant to WUND's diabetic foot ulcer program and broader wound-healing indication.

Others

• Zhittya Genesis Medicine: Zhittya Genesis Medicine is WUND's licensor and de facto R&D partner, developing the underlying FGF-1 therapies. Including it as a peer captures the upstream scientific counterparty that drives WUND's entire portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat1 record

Key risks7 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/wundhealingbiopharmaceuticals
• Xx.com/WundHealing

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WUND Healing Biopharmaceuticals